Wolff–Parkinson–White syndrome (WPW) is one of several disorders of the conduction system of the heart that are commonly referred to as pre-excitation syndromes. WPW is caused by the presence of an abnormal accessory electrical conduction pathway between the atria and the ventricles. Electrical signals travelling down this abnormal pathway (known as the bundle of Kent) may stimulate the ventricles to contract prematurely, resulting in a unique type of supraventricular tachycardia referred to as an atrioventricular reciprocating tachycardia.The incidence of WPW is between 0.1% and 0.3% in the general population.Sudden cardiac death in people with WPW is rare (incidence of less than 0.6%), and is usually caused by the propagation of an atrial tachydysrhythmia (rapid and abnormal heart rate) to the ventricles by the abnormal accessory pathway.
Wolff–Parkinson–White syndrome (WPW) is one of several disorders of the conduction system of the heart that are commonly referred to as pre-excitation syndromes. WPW is caused by the presence of an abnormal accessory electrical conduction pathway between the atria and the ventricles. Electrical signals travelling down this abnormal pathway (known as the bundle of Kent) may stimulate the ventricles to contract prematurely, resulting in a unique type of supraventricular tachycardia referred to as an atrioventricular reciprocating tachycardia.The incidence of WPW is between 0.1% and 0.3% in the general population.Sudden cardiac death in people with WPW is rare (incidence of less than 0.6%), and is usually caused by the propagation of an atrial tachydysrhythmia (rapid and abnormal heart rate) to the ventricles by the abnormal accessory pathway.
AV nodal reentrant tachycardia (AVNRT), or atrioventricular nodal reentrant tachycardia, is a type of tachycardia (fast rhythm) of the heart. It is a type of supraventricular tachycardia (SVT), meaning that it originates from a location within the heart above the bundle of His. AV nodal reentrant tachycardia is the most common regular supraventricular tachycardia. It is more common in women than men (approximately 75% of cases occur in females). The main symptom is palpitations. Treatment may be with specific physical maneuvers, medication, or, rarely, synchronized cardioversion. Frequent attacks may require radiofrequency ablation, in which the abnormally conducting tissue in the heart is destroyed.
AVNRT occurs when a reentry circuit forms within or just next to the atrioventricular node. The circuit usually involves two anatomical pathways: the fast pathway and the slow pathway, which are both in the right atrium. The slow pathway (which is usually targeted for ablation) is located inferior and slightly posterior to the AV node, often following the anterior margin of the coronary sinus. The fast pathway is usually located just superior and posterior to the AV node. These pathways are formed from tissue that behaves very much like the AV node, and some authors regard them as part of the AV node.
The fast and slow pathways should not be confused with the accessory pathways that give rise to Wolff-Parkinson-White syndrome (WPW syndrome) or atrioventricular reciprocating tachycardia (AVRT). In AVNRT, the fast and slow pathways are located within the right atrium close to or within the AV node and exhibit electrophysiologic properties similar to AV nodal tissue. Accessory pathways that give rise to WPW syndrome and AVRT are located in the atrioventricular valvular rings. They provide a direct connection between the atria and ventricles, and have electrophysiologic properties similar to ventricular myocardium.
ventricular premature complexes and idioventricular rhythm identification is important in the ICU ..they may run into arryhthmias..look over my seminar...
any queries...
A comprehensive approach to Atrial Fibrillation. Everything you need to know about Atrial fibrillation. Including recent 2014 AHA guidelines of management.
AV nodal reentrant tachycardia (AVNRT), or atrioventricular nodal reentrant tachycardia, is a type of tachycardia (fast rhythm) of the heart. It is a type of supraventricular tachycardia (SVT), meaning that it originates from a location within the heart above the bundle of His. AV nodal reentrant tachycardia is the most common regular supraventricular tachycardia. It is more common in women than men (approximately 75% of cases occur in females). The main symptom is palpitations. Treatment may be with specific physical maneuvers, medication, or, rarely, synchronized cardioversion. Frequent attacks may require radiofrequency ablation, in which the abnormally conducting tissue in the heart is destroyed.
AVNRT occurs when a reentry circuit forms within or just next to the atrioventricular node. The circuit usually involves two anatomical pathways: the fast pathway and the slow pathway, which are both in the right atrium. The slow pathway (which is usually targeted for ablation) is located inferior and slightly posterior to the AV node, often following the anterior margin of the coronary sinus. The fast pathway is usually located just superior and posterior to the AV node. These pathways are formed from tissue that behaves very much like the AV node, and some authors regard them as part of the AV node.
The fast and slow pathways should not be confused with the accessory pathways that give rise to Wolff-Parkinson-White syndrome (WPW syndrome) or atrioventricular reciprocating tachycardia (AVRT). In AVNRT, the fast and slow pathways are located within the right atrium close to or within the AV node and exhibit electrophysiologic properties similar to AV nodal tissue. Accessory pathways that give rise to WPW syndrome and AVRT are located in the atrioventricular valvular rings. They provide a direct connection between the atria and ventricles, and have electrophysiologic properties similar to ventricular myocardium.
ventricular premature complexes and idioventricular rhythm identification is important in the ICU ..they may run into arryhthmias..look over my seminar...
any queries...
A comprehensive approach to Atrial Fibrillation. Everything you need to know about Atrial fibrillation. Including recent 2014 AHA guidelines of management.
Pre-excitation Syndromes is a group of ECG and Electrophysiological abnormalities in which
The atrial impulses are conducted partly or completely, PREMATURELY, to the ventricles via a mechanism other than the normal AV-node *
Associated with a wide array of tachycardias with both normal QRS and prolonged QRS durations
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
2. SVT
• SVT defined as tachycardias (atrial and/or ventricular rates in excess of 100
bpm at rest), the mechanism of which involves tissue from the His bundle
or above.
• These SVTs include
- inappropriate sinus tachycardia,
- AT (including focal and multifocal AT),
- macroreentrant AT (including typical atrial flutter),
- junctional tachycardia,
- AVNRT, and various forms of accessory pathway-mediated reentrant
tachycardias.
4. PSVT
• A clinical syndrome characterized by the presence of a regular and
rapid tachycardia of abrupt onset and termination. These features are
characteristic of AVNRT or AVRT, and less frequently, AT.
• PSVT represents a subset of SVT
6. Classification of PSVT
• Short R-P
• AVRT(slow-fast)
• AVNRT
• Long R-P
• Atypical forms of the AVNRT (fast-slow)or
• Most atrial tachycardias, SNRT
• PJRT
7. AVNRT
• A reentrant tachycardia involving 2 functionally distinct pathways,
generally referred to as "fast" and "slow" pathways. Most commonly,
the fast pathway is located near the apex of Koch’s triangle, and the
slow pathway inferoposterior to the compact AV node tissue. Variant
pathways have been described, allowing for “slow-slow” AVNRT.
• Two types
- Typical
- Atypical
8. TYPICAL VS ATYPICAL
• AVNRT in which a slow pathway serves as the anterograde limb of the
circuit and the fast pathway serves as the retrograde limb (also called
“slow-fast AVNRT").
• AVNRT in which the fast pathway serves as the anterograde limb of
the circuit and a slow pathway serves as the retrograde limb (also
called “fast-slow AV node reentry”) or a slow pathway serves as the
anterograde limb and a second slow pathway serves as the retrograde
limb (also called “slow-slow AVNRT”).
9. AVRT
• A reentrant tachycardia, the electrical pathway of which requires an
accessory pathway, the atrium, atrioventricular node (or second
accessory pathway), and ventricle.
- Orthodromic AVRT
- Antidromic AVRT
10. ORTHODROMIC
• An AVRT in which the re entrant impulse uses the accessory pathway
in the retrograde direction from the ventricle to the atrium, and the
AV node in the anterograde direction.
• The QRS complex is generally narrow or may be wide because of pre-
existing bundle branch block or aberrant conduction.
11. ANTIDROMIC
• An AVRT in which the re entrant impulse uses the accessory pathway
in the anterograde direction from the atrium to the ventricle, and the
AV node for the retrograde direction.
• Occasionally, instead of the AV node, another accessory pathway can
be used in the retrograde direction, which is referred to as pre-excited
AVRT. The QRS complex is wide (maximally pre-excited).
12. ACCESSORY PATHWAY
• Defined as an extranodal AV pathway that connects the myocardium
of the atrium to the ventricle across the AV groove. Accessory
pathways can be classified by
- their location,
- type of conduction (decremental or nondecremental), and
-Whether they are capable of conducting anterogradely,
retrogradely, or in both directions.
• Accessory pathways of other types (such as atriofascicular, nodo-
fascicular, nodo-ventricular, and fasciculoventricular pathways) are
uncommon
13. EPIDEMIOLOGY
• the prevalence of SVT in the general population is 2.25 per 1,000
persons .
• When adjusted by age and sex in the U.S. population, the incidence of
PSVT is estimated to be 36 per 100,000 persons per year .
• There are approximately 89,000 new cases per year and 570,000
persons with PSVT .
14. • Compared with patients with cardiovascular disease, those with PSVT
without any cardiovascular disease are younger (37 vs 69 years) and
have faster PSVT (186 bpm vs 155 bpm).
• Women have twice the risk of men of developing PSVT .
20. CLINICAL FEATURES
• SVT symptom onset often begins in adulthood.
• the mean age of symptom onset was 32±18 years of age for AVNRT,
versus 23±14 years of age for AVRT .
• In contrast, in a study conducted in pediatric populations, the mean
ages of symptom onset of AVRT and AVNRT were 8 and 11 years,
respectively
21. • In comparison with AVRT, patients with AVNRT are more likely to be
female, with an age of onset >30 years . AVNRT onset has been
reported after the age of 50 years in 16% and before the age of 20
years in 18%.
• Among women with SVT and no other cardiovascular disease, the
onset of symptoms occurred during childbearing years (e.g., 15 to 50
years) in 58%
22. PREGNANCY
• The first onset of SVT occurred in only 3.9% of women during
pregnancy, but among women with an established history of SVT, 22%
reported that pregnancy exacerbated their symptoms.
23. SYMPTOMS
• SVT has an impact on quality of life, which varies according to
- the frequency of episodes,
- the duration of SVT, and
- whether symptoms occur not only with exercise but also at
rest.
• The criteria for panic disorder were fulfilled in 67% of patients with
SVT that remained unrecognized after their initial evaluation.
24. • AVNRT is typically paroxysmal and may occur spontaneously or upon
provocation with exertion, caffeine, alcohol, beta-agonists
(salbutamol) or sympathomimetics (amphetamines).
• Patients will typically complain of the sudden onset of rapid, regular
palpitations. The patient may experience a brief fall in blood pressure
causing presyncope or occasionally syncope.
25. • If the patient has underlying coronary artery disease the patient may
experience chest pain similar to angina like tight band around the
chest radiating to left arm or left jaw.
• The patient may complain of shortness of breath, anxiety and
occasionally polyuria due to elevated atrial pressure releasing atrial
natriuretic peptide.
26. • The tachycardia typically ranges between 140-280 bpm and is regular
in nature. It may cease spontaneously (and abruptly) or continue
indefinitely until medical treatment is sought.
• The condition is generally well tolerated and is rarely life threatening
in patients with pre-existing heart disease
27. COMPARISON
• When AVNRT and AVRT are compared, symptoms appear to differ
substantially.
• Patients with AVNRT more frequently describe symptoms of “shirt
flapping” or “neck pounding” that may be related to pulsatile
reversed flow when the atria contract against a closed tricuspid valve
(cannon a-waves).
28. • During invasive study of patients with AVNRT and AVRT, both
arrhythmias decreased arterial pressure and increased left atrial
pressure, but simulation of SVT mechanism by timing the pacing of
the atria and ventricles showed significantly higher left atrial pressure
in simulated AVNRT than in simulated AVRT.
• Polyuria is particularly common with AVNRT and is related to higher
right atrial pressures and elevated levels of atrial natriuretic protein in
patients with AVNRT compared with patients who have AVRT
29. SYNCOPE
• True syncope is infrequent with SVT, but complaints of light-
headedness are common.
• Elderly patients with AVNRT are more prone to syncope or near-
syncope than are younger patients, but the tachycardia rate is
generally slower in the elderly
• The drop in blood pressure during SVT is greatest in the first 10 to 30
seconds and somewhat normalizes within 30 to 60 seconds, despite
minimal changes in rate.
• Shorter ventriculoatrial intervals are associated with a greater mean
decrease in BP
30. DRIVING
• In a study of the relationship of SVT with driving, 57% of patients with
SVT experienced an episode while driving, and 24% of these
considered it to be an obstacle to driving .
• This was most common in patients who had experienced syncope or
near-syncope.
• Among patients who experienced SVT while driving, 77% felt fatigue,
50% had symptoms of near-syncope, and 14% experienced syncope.
34. AVNRT
• Regular tachycardia 145-250 bpm.
• QRS complexes usually narrow (< 120 ms)
• ST-segment depression may be seen with or without underlying coronary
artery disease.
• QRS alternans – phasic variation in QRS amplitude associated with AVNRT
and AVRT
• P waves if visible exhibit retrograde conduction with P-wave inversion in
leads II, III, aVF.
• P waves may be buried in the QRS complex, visible after the QRS complex,
or very rarely visible before the QRS complex.
• Pseudo R’ wave may be seen in V1 or V2. Pseudo S waves may be seen in
leads II, III or aVF.
42. VAGAL MANEUVERS
• Any condition that increase in the activity of the vagal nerve and
sympathetic with-drawal, slowing conduction through the
atrioventricular node
• Vagal maneuvers and administration of adenosine are useful in the
diagnosis and treatment of narrow-complex supraventricular
tachycardias.
43. DIAGNOSIS
• The resulting slowing of the heart rate often confirms the diagnosis of
sinus tachycardia, atrial fibrillation, or atrial flutter and
• can frequently terminate atrioventricular nodal reentrant tachycardia
and atrioventricular reciprocating tachycardia
44. VAGAL STIMULATION
Gagging and/or vomiting
Swallowing
Intracardiac catheter placement
Medical antishock trousers (MAST garments)
Nasogastric tube placement
Squatting
Trendelenburg position
Carotid sinus massage
Valsalva maneuver (standard or modified technique)
Water immersion, especially cold water immersion
(diving reflex)
Eyeball pressure (oculocardiac reflex)
Breath holding
Rectal examination
Coughing
Deep respirations
45. CAROTID SINUS MASSAGE
• place in a supine or semirecumbent position and take normal breathing
• instructed to exhale forcefully against a closed glottis after a normal
inspiratory effort.
• Signs of adequacy include neck vein distension, increased tone in the
abdominal wall muscles, and a flushed face.
• The patient should maintain the strain for 10 to 15 seconds and then
release it and resume normal breathing.
46. CAROTID SINUS MASSAGE
• The patient is placed in the supine position with the neck
hyperextended to maximize access to the carotid artery.
• The carotid sinus is usually located inferior to the angle of the
mandible at the level of the thyroid cartilage near the arterial impulse
.
• Pressure is applied to one carotid sinus for 5 to 10 seconds. Although
pulsatile pressure via vigorous circular motion may be more effective,
steady pressure is recommended because it may be more
reproducible .
47. • If the expected response is not obtained, the procedure is repeated
on the other side after a one- to two-minute delay
• Contraindication
- bruit
- prior h/o CVA/TIA
- age >65yrs
48. MODIFIED VALSALVA MANEUVER
• A modified Valsalva maneuver, which involves the standard strain (40
mmHg pressure for 15 seconds in the semirecumbent position)
followed by supine repositioning with 15 seconds of passive leg raise
at a 45 degree angle.
• It has been shown to be more successful in restoring sinus rhythm for
patients with SVT
49.
50.
51. • Another vagal maneuver based on the classic diving reflex consists of
applying an ice-cold, wet towel to the face.
• in a laboratory setting, facial immersion in water at 10°C (50°F) has
proved effective in terminating tachycardia, as well .
• One study involving 148 patients with SVT demonstrated that Valsalva
was more successful than carotid sinus massage, and switching from
technique to the other resulted in an overall success rate of 27.7%.
52. ADENOSINE
• Adenosine has been shown in randomized trials in the emergency
department or prehospital setting to effectively terminate SVT that is
due to either AVNRT or AVRT, with success rates ranging from 78% to
96%.
• Although patients may experience side effects, such as chest
discomfort, shortness of breath, and flushing, serious adverse effects
are rare because of the drug’s very short half-life .
53. • Adenosine may also be useful diagnostically, to unmask atrial flutter
or AT, but it is uncommon for adenosine to terminate these atrial
arrhythmias .
• 6-mg rapid IV bolus (injected into IV as proximal or as close to the
heart as possible), administered over 1–2 s, followed by rapid saline
flush
• If no result within 1–2 min, 12-mg rapid IV bolus; can repeat 12-mg
dose 1 time. The safe use of 18-mg bolus doses has been reported
54. PRECAUTION
• Reactive airway disease
• Concomitant use of verapamil or digoxin
• WPW
• 3mg IV in
- central line
- transplant
55. CCB
• Intravenous diltiazem and verapamil have been shown to terminate
SVT in 64% to 98% of patients. These drugs should be used only in
hemodynamically stable patients.
• A slow infusion of either drug up to 20 minutes may lessen the
potential for hypotension .
• It is important to ensure that tachycardia is not due to VT or pre-
excited AF because patients with these rhythms who are given
diltiazem or verapamil may become hemodynamically unstable or
may have accelerated ventricular rate, which may lead to ventricular
fibrillation.
56. • These agents are especially useful in patients who cannot tolerate
beta blockers or experience recurrence after conversion with
adenosine.
• Diltiazem and verapamil are not appropriate for patients with
suspected systolic heart failure
57.
58. B BLOCKER
• Evidence for the effectiveness of beta blockers in terminating SVT is
limited.
• In a trial that compared esmolol with diltiazem, diltiazem was more
effective in terminating SVT .
• Nonetheless, beta blockers have an excellent safety profile, so it is
reasonable to use intravenous beta blockers to attempt to terminate
SVT in hemodynamically stable patients
63. LONG TERM MANAGEMENT
• The age of the patient and the type of SVT are major determinants
for choosing optimal chronic therapy.
• The presence of preexcitation on electrocardiogram prompts an
evaluation for stratification of risk of cardiac arrest plus the avoidance
of digoxin or verapamil therapy. The symptoms during tachycardia
and frequency of episodes.
• the sophistication of the patient’s caretaker, also are important guides
to treatment
65. No treatment option
May be considered for
• older children who can recognise and communicate the onset of
PSVT,
• have infrequent PSVT
• well-tolerated episodes of SVT not associated with preexcitation
• those who can try Valsalva manoeuvre to abort the attack or
• prefer an infrequent visit to emergency room over the chronic
medication.
66. “Pill-in-the-Pocket” Approach
• For patients with infrequent (i.e., no more than a few per year) but
prolonged (i.e., lasting more than one to two hours) episodes of
supraventricular tachycardia that are well tolerated hemodynamically,
or
• for patients who have had only a single episode of supraventricular
tachycardia, another option is to prescribe single-dose pharmacologic
therapy (the “pill in the pocket”) to be taken when needed for an
arrhythmic event.
67. Drugs
• calcium-channel blockers (e.g., 40 to 160 mg of verapamil), exclusively
for patients without preexcitation;
• various betablockers;
• flecainide (100 to 300 mg); and propafenone (150 to 450 mg).
• In one study, 80 percent of episodes of supraventricular tachycardia
were in terrupted within two hours with a combination of diltiazem
and propanolol or with flecainide
68. PHARMACOLOGIC THERAPY
• Patients with recurrent episodes of supraventricular tachycardia
without preexcitation may be treated with prophylactic
antiarrhythmic agents.
75. Atrioventricular Nodal Reentrant Tachycardia – Acute Treatment
COR LOE Recommendations
I B-R Vagal maneuvers are recommended for acute treatment in patients
with AVNRT.
I B-R Adenosine is recommended for acute treatment in patients with
AVNRT.
I B-NR Synchronized cardioversion should be performed for acute
treatment in hemodynamically unstable patients with AVNRT when
adenosine and vagal maneuvers do not terminate the tachycardia
or are not feasible.
I B-NR Synchronized cardioversion is recommended for acute treatment in
hemodynamically stable patients with AVNRT when
pharmacological therapy does not terminate the tachycardia or is
contraindicated.
76. Atrioventricular Nodal Reentrant Tachycardia – Acute Treatment
(cont’d)
COR LOE Recommendations
IIa B-R Intravenous beta blockers, diltiazem, or verapamil are
reasonable for acute treatment in hemodynamically stable
patients with AVNRT.
IIb C-LD Oral beta blockers, diltiazem, or verapamil may be
reasonable for acute treatment in hemodynamically stable
patients with AVNRT.
IIb C-LD Intravenous amiodarone may be considered for acute
treatment in hemodynamically stable patients with AVNRT
when other therapies are ineffective or contraindicated.
77. Atrioventricular Nodal Reentrant Tachycardia – Ongoing Management
COR LOE Recommendations
I B-R Oral verapamil or diltiazem is recommended for ongoing management in
patients with AVNRT who are not candidates for, or prefer not to undergo,
catheter ablation.
I B-RN Catheter ablation of the slow pathway is recommended in patients with
AVNRT.
I B-NR Oral beta blockers are recommended for ongoing management in patients
with AVNRT who are not candidates for, or prefer not to undergo, catheter
ablation.
IIa B-NR Flecainide or propafenone is reasonable for ongoing management in
patients without structural heart disease or ischemic heart disease who
have AVNRT and are not candidates for, or prefer not to undergo, catheter
ablation and in whom beta blockers, diltiazem, or verapamil are ineffective
or contraindicated.
78. Atrioventricular Nodal Reentrant Tachycardia – Ongoing Management
(cont’d)
COR LOE Recommendations
IIa B-NR Clinical follow-up without pharmacological therapy or ablation is
reasonable for ongoing management in minimally symptomatic patients
with AVNRT.
IIb B-R Oral sotalol or dofetilide may be reasonable for ongoing management in
patients with AVNRT who are not candidates for, or prefer not to undergo,
catheter ablation.
IIb B-R Oral digoxin or amiodarone may be reasonable for ongoing treatment of
AVNRT in patients who are not candidates for, or prefer not to undergo,
catheter ablation.
IIb C-LD Self-administered (“pill-in-the-pocket”) acute doses of oral beta blockers,
diltiazem, or verapamil may be reasonable for ongoing management in
patients with infrequent, well- tolerated episodes of AVNRT.
79. Management of Patients With Symptomatic Manifest or
Concealed Accessory Pathways
Manifest and Concealed Accessory Pathways
80. Symptomatic Manifest or Concealed Accessory Pathways –
Acute Treatment
COR LOE Recommendations
I B-R Vagal maneuvers are recommended for acute treatment in patients with
orthodromic AVRT.
I B-R Adenosine is beneficial for acute treatment in patients with orthodromic
AVRT.
I B-NR Synchronized cardioversion should be performed for acute treatment in
hemodynamically unstable patients with AVRT if vagal maneuvers or
adenosine are ineffective or not feasible.
I B-NR Synchronized cardioversion is recommended for acute treatment in
hemodynamically stable patients with AVRT when pharmacological
therapy is ineffective or contraindicated.
81. Symptomatic Manifest or Concealed Accessory Pathways –
Acute Treatment (cont’d)
COR LOE Recommendations
I B-NR Synchronized cardioversion should be performed for acute treatment in
hemodynamically unstable patients with pre-excited AF.
I C-LD Ibutilide or intravenous procainamide is beneficial for acute treatment in
patients with pre-excited AF who are hemodynamically stable.
IIa B-R Intravenous diltiazem, verapamil (Level of Evidence: B-R) or beta blockers
(Level of Evidence: C-LD) can be effective for acute treatment in patients
with orthodromic AVRT who do not have pre-excitation on their resting
ECG during sinus rhythm.
C-LD
82. Symptomatic Manifest or Concealed Accessory Pathways –
Acute Treatment (cont’d)
COR LOE Recommendations
IIb B-R Intravenous beta blockers, diltiazem, or verapamil might be
considered for acute treatment in patients with orthodromic
AVRT who have pre-excitation on their resting ECG and
have not responded to other therapies .
III:
Harm
C-LD Intravenous digoxin, intravenous amiodarone, intravenous or
oral beta blockers, diltiazem, and verapamil are potentially
harmful for acute treatment in patients with pre-excited AF.
83. Management of Patients With Symptomatic Manifest or
Concealed Accessory Pathways
Manifest and Concealed Accessory Pathways
84. Symptomatic Manifest or Concealed Accessory Pathways –
Ongoing Management
COR LOE Recommendations
I B-NR Catheter ablation of the accessory pathway is recommended in
patients with AVRT and/or pre- excited AF.
I C-LD Oral beta blockers, diltiazem, or verapamil are indicated for
ongoing management of AVRT in patients without pre-excitation on
their resting ECG.
IIa B-R Oral flecainide or propafenone is reasonable for ongoing
management in patients without structural heart disease or
ischemic heart disease who have AVRT and/or pre-excited AF and
are not candidates for, or prefer not to undergo, catheter ablation.
85. Symptomatic Manifest or Concealed Accessory Pathways –
Ongoing Management (cont’d)
COR LOE Recommendations
IIb B-R Oral dofetilide or sotalol may be reasonable for ongoing
management in patients with AVRT and/or pre-excited AF who are
not candidates for, or prefer not to undergo, catheter ablation.
IIb C-LD Oral amiodarone may be considered for ongoing management in
patients with AVRT and/or pre- excited AF who are not candidates
for, or prefer not to undergo, catheter ablation and in whom beta
blockers, diltiazem, flecainide, propafenone, and verapamil are
ineffective or contraindicated.
86. Symptomatic Manifest or Concealed Accessory Pathways –
Ongoing Management (cont’d)
COR LOE Recommendations
IIb C-LD Oral beta blockers, diltiazem, or verapamil may be reasonable for
ongoing management of orthodromic AVRT in patients with pre-
excitation on their resting ECG who are not candidates for, or prefer
not to undergo, catheter ablation.
IIb C-LD Oral digoxin may be reasonable for ongoing management of
orthodromic AVRT in patients without pre-excitation on their resting
ECG who are not candidates for, or prefer not to undergo, catheter
ablation.
III:
Harm
C-LD Oral digoxin is potentially harmful for ongoing management in
patients with AVRT or AF and pre- excitation on their resting ECG.